The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294
University of Southern California, Los Angeles, California, United States, 90007
University of Kentucky, Lexington, Kentucky, United States, 40506
Johns Hopkins Medicine Brain Science Institute, Baltimore, Maryland, United States, 21205
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States, 01805
University of Virginia Health System, Charlottesville, Virginia, United States, 22903
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 81 Years
ALL
No
AB Science,
Albert Ludolph, MD, PhD, PRINCIPAL_INVESTIGATOR, Department of Neurology, University of Ulm, Germany
2023-12